Abstract
Purpose: To assess the feasibility of skin electronic brachytherapy (EBT) and present the dosimetric and clinical characteristics of our initial experience. Materials and Methods: From May 2013 to November 2013, a total of 211 lesions in 191 patients were treated with primary EBT for skin cancer on a prospective registry. All patients received radiation therapy using the XOFT Axxent HDR EBT system to a dose of 40Gy in 8 fractions of 5Gy each given twice weekly with a minimum interval of 48 hours. Patient selection criteria included Age over 60 years, lesion size less than 4 cm diameter, less than 5mm depth, and basal or squamous cell carcinoma histopathology. Results: All patients successfully completed their planned treatment course. The clinical parameters of Age, lesion location, lesion surface diameter, lesion depth, histopathology and comorbidities as well as the dosimetric parameters of applicator cone size, prescribed depth dose, surface dose, dwell time, use of cutouts and correlating cutout factors will be presented. Conclusion: In our experience, the use of EBT for select skin cancers is highly feasible. A prospective registry trial is ongoing that will allow careful clinical and dosimetric correlation with toxicities and outcomes.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
